Overview: H. Pylori Antigen Rapid TestIntroduction: The H. Pylori Antigen Rapid Test is a diagnostic tool designed to detect Helicobacter pylori antigens in stool or saliva samples, facilitating the screening of H. pylori infections. This bacterial infection, commonly associated with gastric ulcers, gastritis, and gastric cancer, presents with stomach pain, bloating, and severe complications like perforation or malignancy if untreated, particularly in populations with poor sanitation or high prevalence. Per the 2023 American Gastroenterological Association guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a practical tool for rapid diagnosis in primary care. This rapid diagnostic falls under bacteriology and targets individuals with dyspepsia or ulcer symptoms, addressing the challenge of identifying H. pylori to guide eradication therapy with proton pump inhibitors and antibiotics like amoxicillin or clarithromycin. With morbidity rates elevated due to chronic infection, the test supports public health efforts by enabling early detection, facilitating treatment monitoring, and reducing gastric cancer incidence. Its dual-sample capability enhances its utility.Other Names: H. Pylori Rapid Test.FDA Status: FDA approved, CLIA certified for bacteriology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Meridian Bioscience, this test advanced H. pylori detection, providing a non-invasive alternative to urea breath tests.Purpose: The test screens for H. pylori antigens to guide infection diagnosis, assess treatment success, and inform treatment and prevention strategies.Test Parameters: Presence of H. pylori Antigen, detected with high specificity to indicate active infection, typically detectable during the active phase, persisting until eradicated.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report stomach pain, bloating, or ulcer history.Specimen: Stool 5-10 gm, Saliva 1-2 mL, collected using sterile containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on stomach pain, bloating, ulcer history, or recent antibiotic/proton pump inhibitor use, as well as any family history of gastric cancer.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including cancer, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent antibiotic use can affect results. Correlation with urea breath test or stool antigen follow-up is recommended to confirm findings.Clinical Significance: A positive result indicates H. pylori infection, necessitating eradication therapy. A negative result may require follow-up testing if symptoms persist, especially post-treatment to confirm eradication.Specialist Consultation: Gastroenterologists should be consulted for case management, treatment planning, and coordination with chronic disease programs.Additional Supporting Tests: Urea breath test, stool antigen retest, or endoscopy for confirmation.Test Limitations: The test may produce false negatives post-treatment or false positives due to colonization, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AGA Guidelines 2023, Gut 2024, Journal of Clinical Microbiology 2025.